Une ancienne boîte de poulet St-Hubert, retrouvée par hasard dans l’entretoit d’un chalet, a été remise à la famille Martin en échange d'un don.

Élise Gravel est une dessinatrice québécoise qui fait des petits dessins tout mignons pour les enfants.

On apprend aujourd’hui que certains CPE, subventionnés avec votre argent, pratiquent une discrimination scandaleuse dans l’accueil des enfants.

Donald Trump a indiqué mardi qu’il comptait nommer Elon Musk à la tête d’un ministère nouvellement créé de l’«efficacité gouvernementale»

Via Rail's service standards have eroded substantially over the last decade, with many more trains arriving late.

Total greenhouse gas emissions from Alberta's oilsands have remained relatively flat for the last few years but could climb yet again in 2024 as the industry ratchets up oil production, according to a new report released Thursday.

While public transit in many Canadian cities is struggling with rising fares and falling ridership, one Ontario community has more than doubled its transit use in the past two years. Orangeville has made its buses free, joining a list of much larger communities that have gone fare-free.

Supporters say the Supreme Court of Canada's so-called Jordan ruling in 2016 has sped up proceedings and strengthened Charter rights for prompt justice. But some victims say the time limits for trials work in criminals' favour and cases continue to collapse because those limits are breached. 

Labour Minister Steven MacKinnon has sent labour disputes at ports in Quebec and British Columbia to binding arbitration and has ordered people back to work after the disputes reached what he called a "total impasse."

Canada’s privacy commissioner has launched an investigation into the World Anti-Doping Agency (WADA) and “its handling of biological samples collected from athletes.”

Ontario Premier Doug Ford appears to be dipping his toe into new territory — talking about removing Mexico from the North American trade agreement.

Former B.C. premier John Horgan has died at the age of 65, CBC News has confirmed. In June this year, Horgan told CBC that he had been diagnosed with cancer for the third time during a routine followup appointment for his previous throat cancer.

“Magic mirror in the hand, who has the most wrinkles in the land?” has transcended from Snow White to 21st century camera technology.

THOUSANDS of fans stay up late to watch the English Premier League. But the UK leaving the EU could change all that.

SEMI Radradra’s sister has directly contradicted reports in the Fiji Times that her brother was leaving the NRL for French rugby.

Le chanteur Zach Bryan aurait demandé à son ex-copine Brianna LaPaglia de ne pas parler de leur relation en lui offrant 12 millions de dollars.

Gros succès en France, le drame biographique est présenté samedi au Festival Cinemania.

Un premier spectacle d’humour en solo, intitulé «Après seulement 32 ans d’absence sur scène».

A MINE could deliver water security to vegetable growers on the Lindenow Flats in East Gippsland.

KOROROIT MP Marlene Kairouz will become Victoria’s new minister for consumer affairs, gambling and liquor regulation.

HOW do you stop the young folk from heading to the big smoke? You build a school and teach them how to be jackaroos and jillaroos.

Many parents opt for more expensive baby milk, equating higher costs with better quality, the watchdog found.

Thousands of drivers on ride-hailing and food delivery app Bolt have won a legal claim to be classed as workers.

Recently-released dolls tied to the new Wicked movie inadvertently carry the address of an adult website.

Office for National Statistics data suggests homeworkers get more sleep and exercise on average.

Those who work in public administration and defence operate in the most heavily unionised sector of the labour market.

The Opposition Leader, who has three young children, says all his election travel was declared and above board.

A Muslim bigamist will have his court costs paid by the federal government.

La découverte d’un circuit cérébral impliqué dans l’effet antidouleur des placebos pourrait permettre le développement de traitements analgésiques.

The secretary of the Union Ayush Ministry, Dr Rajesh Kotecha, will inaugurate the 61st Ayurveda Seminar organized by the Kottakkal Aryavaidyasala (Kottakkal AVS) on November 10 at Kottakkal in

The Department of Pharmaceuticals (DoP) has upheld the retail price fixation of National Pharmaceutical Pricing Authority (NPPA) for Mumbai─based Aristo Pharmaceuticals for its multivitamin tablets with

An inter─ministerial committee formed by the Union health ministry has recommended amendments to the Food Safety and Standards Act, 2006 and regulations on nutraceuticals and health supplements, to shift regulation of

Accumold, with over 40 years of experience in micromoulding technology, is set to participate at Compamed, taking place in Düsseldorf, Germany, from 11-14 November. The company will highlight its small and complex parts for medical device OEMs.

Bormioli Pharma has announced a partnership with Chiesi, an international, research-focused biopharmaceutical company (Chiesi Group), to supply Carbon Capture PET bottles.

Rob Pitts, sales manager at Tri-Tech 3D, UK provider of Stratasys 3D printing solutions, explores how additive manufacturing (AM) can help speed up surgical workflows and reduce costs by transforming anatomical modelling.

Humans and pigs could both serve as mixing vessels for a bird flu–seasonal flu hybrid, posing a risk of wider spread

The discovery of a new prime number highlights the rising price of mathematical gold

“Going viral” appears to be more than just a catchphrase when it comes to the rampant spread of misinformation

This year won’t just be the hottest on record—it could be the first to surpass 1.5 degrees Celsius. The Paris climate accord aims to keep warming below that level when looking over multiple years

It is difficult to disentangle Russian and Chinese scientists from international science cooperation. That is a good thing

The new Trump administration is likely to reduce subsidies for Affordable Care Act insurance plans and roll back Medicaid coverage. Public health authorities worry that antivaccine activist Robert F. Kennedy, Jr., will be empowered

A mysterious electromagnetic mechanism may be more important than the firing of neurons in our brain to explain our awareness

The 3.2-million-year-old human ancestor known as Lucy rose to fame through an incredible combination of circumstances

A fee created to push oil and gas companies to plug methane leaks could be axed by the incoming Trump administration, hampering efforts to curb the potent greenhouse gas

Researchers at Rice University have developed a magnetoelectric material that converts a magnetic field into an electric field. The material can be formulated such that it can be injected into the body, near a neuron, and then an alternating magnetic field can be applied to the area from outside the body. Magnetic fields are very […]

Researchers at the Wyss Institute at Harvard University have developed a microfluidic chip that can recreate some of the features of radiation-induced lung injury. The lungs are very sensitive to radiation, and this can limit the application of radiotherapy to treat cancer. Accurately modeling radiation-induced lung injury could assist in developing new methods to prevent […]

On October 8, 2024, Drug Channels Institute will release our 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry.

9 chapters, 350+ pages, 178 exhibits, 750+ endnotes: There is nothing else available that comes close to this valuable resource.

We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2024-25 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 8.

• Review pricing/license options and place a preorder

• Download a free pre-publication report overview (including key industry trends, What's New in this edition, the Table of Contents, and a List of Exhibits)

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to contact us if you would like to pay by corporate check or ACH.

Special preorder and launch pricing discounts will be valid through October 23, 2024.

Read on for more details.
Read more »

Informa Connnect's Pharma/Biotech GTN Summit
November 18-20, 2024 | W Philadelphia Hotel, Philadelphia, PA
Drug Channels Readers Receive 15% Off* with Code 24DGC15.

View the Complete Agenda

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you:

• Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble

• Optum Rx joins the private label biosimilar bandwagon

• Biosimilars boom for provider-administered drugs

• Fresh evidence of how copay accumulators hurt patients

Plus, words of wisdom from Cencora's soon-to-be-former CEO Steve Collis.

P.S. Join my more than 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community.

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Read more »

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). The FTC rightly calls out how the gross-to-net bubble can raise patients’ out-of-pocket costs, while also acknowledging how rebates can reduce a plan's (but not the patient’s) costs. Apparently, the FTC believes that PBMs’ customers are pretty dumb, because PBMs are able to prevent plans from “appreciating” such healthcare financing dynamics.

Section V.E. of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. I thought it would therefore be fun to take the Wayback Machine to November 2021, when I wrote about this specific topic.

Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Much of the FTC’s description of the drug channel aligns with my commentary. But before you fist pump too hard for Ms. Khan’s FTC, you should pause to reflect on the agency’s legal theories in light of plans’ revealed preferences.

---

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough.

Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Express Scripts will block both the branded reference product and the lower-priced, unbranded—but also interchangeable—version. Meanwhile, Prime Therapeutics will place both versions on its formularies, leaving the choice up to its plan sponsor clients.

Consequently, many commercial payers will adopt the more expensive product instead of the identical—but cheaper—version. As usual, patients will be the ultimate victims of our current drug pricing system.

Below, I explain the weird economics behind this decision, highlight the negative impact on patients, and speculate on what this all could mean for biosimilars’ future. Until plan sponsors break their addiction to rebates, today’s U.S. drug channel problems will remain.
Read more »